Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Pacritinib (Primary) ; Azacitidine; Decitabine
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 08 Jun 2017 Status changed from active, no longer recruiting to discontinued.
- 18 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.
- 05 Aug 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2016.